Summary: Recursion Pharmaceuticals has developed a new method of drug discovery that they claim will lead to 100 new treatments for hard-to-treat rare genetic diseases within 10 years. Christopher Gibson, Ph.D., CEO of Recursion, explains the technology that allows them to rapidly screen through hundreds of candidate treatments for nearly any genetic disease. He also describes why they are opting to screen through old, already existing drugs, instead of developing new ones. Their approach has already led to identification of a potential therapeutic for cerebral cavernous malformation, a finding recently published in <a href="http://www.ncbi.nlm.nih.gov/pubmed/25486933">Circulation </a>. <a href="http://healthcare.utah.edu/publicaffairs/news/2014/recursion.php">Learn more</a>.
